Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 16/20 | 0.46 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7358397 | 0.81 | PARP1 (0.41) | PARP1PKN1PKN2KDM4EL3MBTL1 | |
| SCHEMBL27249587 | 0.80 | PARP1 (0.47) | PARP1PKN1PKN2KDM4EL3MBTL1 | |
| SCHEMBL16497015 | 0.78 | PARP1 (0.49) | PARP1KDM4EL3MBTL1 | |
| SCHEMBL8648021 | 0.75 | LMNA (0.50) | PARP1 | |
| SCHEMBL29829372 | 0.72 | PI4KA (0.47) | PARP1 | |
| SCHEMBL19857549 | 0.72 | KDM4E (0.40) | PARP1PKN1PKN2KDM4EL3MBTL1 | |
| SCHEMBL7363550 | 0.72 | EGLN1 (0.35) | PARP1PKN1PKN2KDM4EL3MBTL1 | |
| SCHEMBL29830227 | 0.71 | HPGD (0.48) | PARP1 | |
| SCHEMBL29829801 | 0.71 | PARP1 (0.54) | PARP1 | |
| SCHEMBL29829541 | 0.71 | EGLN1 (0.49) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | WDR77, POP1, PSMG3 | PARP1 2231/4885PKN1 2746/4885PKN2 2343/4885 |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | WDR77, POP1, PSMG3 | PARP1 2244/4885PKN1 2743/4885PKN2 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.